0.00Open1.20Pre Close0 Volume0 Open Interest35.00Strike Price0.00Turnover0.00%IV510.46%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry1.20Time Value100Contract SizeAmericanOptions Type--Delta--Gamma4.94Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Replimune Stock Discussion
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US)$
$BeiGene(BGNE.US)$
$ACADIA Pharmaceuticals(ACAD.US)$
$Madrigal Pharmaceuticals(MDGL.US)$
$Rhythm Pharmaceuticals(RYTM.US)$
$Revolution Medicines(RVMD.US)$
$Kymera Therapeutics(KYMR.US)$
$AbCellera Biologics(ABCL.US)$
$Bicycle Therapeutics(BCYC.US)$
$Edgewise Therapeutics(EWTX.US)$
$Immunocore(IMCR.US)$
$Kodiak Sciences(KOD.US)$
$Roivant Sciences(ROIV.US)$
...
NEWS
Replimune Group, Inc. announced positive interim results from the ARTACUS Phase 1/2 clinical trial evaluating RP1 monotherapy for skin cancers in transplant patients, showing a 34.8% overall response rate with good durability. The treatment was well-tolerated and resulted in immune activation.
The reason why I am interested in oncolytic virus is that the virus itself is a kind of drug, and at the same time, the virus can become the carrier of other drugs. This dual property is not possessed by other drugs at present, and it is up to us to fully exploit this function. $Replimune(REPL.US)$ $Candel Therapeutics(CADL.US)$
No comment yet